Wockhardt Limited has released its latest Investor Presentation, highlighting a remarkable 76% year-on-year growth in EBITDA and a 14% increase in total income to INR 2,879 Cr.

The company is focusing on combating antimicrobial resistance with its novel antibiotics, ZAYNICH® and MIQNAF®, and anticipates strong growth in biosimilars, especially diabetes-related products.

Wockhardt's strategic debt reduction and comprehensive R&D efforts position it well for future expansion in both domestic and global markets.

Access the full presentation on their website.